Custom Search


Tuesday 14 September 2004

Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide.

By: Enting RH, Demopoulos A, DeAngelis LM, Abrey LE.

Neurology 2004 Sep 14;63(5):901-3

The authors evaluated the efficacy of a combination of rituximab and temozolomide for recurrent or refractory primary CNS lymphoma (PCNSL). Fifteen patients with a median age of 69 years had a 53% objective response rate with acceptable toxicity. Median overall survival is 14 months and median progression free survival of responding patients is 7.7 months. This combination merits further study and provides a reasonable therapeutic alternative for older patients with progressive PCNSL.

Use of this site is subject to the following terms of use